Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Lymphoid 2Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Single Person × Thoracic × Clear all
NCT04585477 2026-02-10

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Stanford University

Phase 2 Recruiting
80 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04767009 2025-04-30

SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Fudan University

Phase 2 Unknown
59 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡